Virtus Family Office LLC Buys New Shares in Gilead Sciences, Inc. $GILD

Virtus Family Office LLC bought a new stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund bought 6,834 shares of the biopharmaceutical company’s stock, valued at approximately $839,000.

A number of other institutional investors also recently modified their holdings of GILD. Brighton Jones LLC lifted its position in shares of Gilead Sciences by 20.6% during the 4th quarter. Brighton Jones LLC now owns 14,359 shares of the biopharmaceutical company’s stock valued at $1,326,000 after acquiring an additional 2,450 shares during the period. Bison Wealth LLC acquired a new position in shares of Gilead Sciences during the 4th quarter valued at $215,000. Sivia Capital Partners LLC raised its holdings in Gilead Sciences by 16.8% during the second quarter. Sivia Capital Partners LLC now owns 4,182 shares of the biopharmaceutical company’s stock worth $464,000 after buying an additional 602 shares during the last quarter. Ieq Capital LLC raised its holdings in Gilead Sciences by 12.0% during the second quarter. Ieq Capital LLC now owns 118,695 shares of the biopharmaceutical company’s stock worth $13,160,000 after buying an additional 12,705 shares during the last quarter. Finally, Diversify Advisory Services LLC raised its holdings in Gilead Sciences by 18.6% during the second quarter. Diversify Advisory Services LLC now owns 4,296 shares of the biopharmaceutical company’s stock worth $516,000 after buying an additional 674 shares during the last quarter. Institutional investors and hedge funds own 83.67% of the company’s stock.

Insider Activity

In other news, CFO Andrew D. Dickinson sold 3,000 shares of the stock in a transaction dated Wednesday, April 15th. The shares were sold at an average price of $140.96, for a total value of $422,880.00. Following the completion of the sale, the chief financial officer owned 176,191 shares in the company, valued at $24,835,883.36. This represents a 1.67% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Johanna Mercier sold 3,000 shares of the stock in a transaction dated Wednesday, April 15th. The shares were sold at an average price of $140.96, for a total transaction of $422,880.00. Following the completion of the sale, the insider owned 128,779 shares of the company’s stock, valued at approximately $18,152,687.84. This represents a 2.28% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 63,000 shares of company stock worth $9,238,250 over the last quarter. Insiders own 0.30% of the company’s stock.

Gilead Sciences News Summary

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Q1 results beat expectations: Gilead reported $2.03 EPS and $6.96B revenue, above consensus, with core products (notably Biktarvy) driving 4.4% year-over-year sales growth. Gilead Sciences (GILD) Tops Q1 Earnings and Revenue Estimates
• Positive Sentiment: Gilead raised its 2026 sales outlook (reiterating solid top-line momentum), which partially offsets concerns about near-term profitability. Gilead raises 2026 sales forecast, cuts profit outlook due to acquisitions
• Neutral Sentiment: Board/shareholder matters and communications: shareholders approved board pay plans at the 2026 meeting; the earnings call transcript and slide deck are available for deeper investor review. Listen to Conference Call
• Neutral Sentiment: Dividend declared: Gilead announced a quarterly dividend of $0.82/share (record June 15; payable June 29), supporting income‑oriented holders. (Company release)
• Negative Sentiment: Massive acquisition-related charges: management flagged roughly $11.5B of acquisition charges and associated financing costs that drove FY‑2026 adjusted EPS guidance down to an expected loss of $0.65–$1.05 per share (vs. prior positive guidance and analyst expectations). That guidance hit is the primary reason the stock is trading lower. Gilead Sciences (GILD) Stock Drops Despite Q1 Beat on Massive Acquisition Charges
• Negative Sentiment: Market reaction and analyst focus: coverage highlights that the firm now expects an adjusted loss due to acquired R&D and transaction costs, prompting some analysts to re-evaluate near-term earnings models and risk premiums. Gilead Sciences Expects Loss This Year on Acquired R&D Expenses

Gilead Sciences Stock Performance

Shares of GILD stock opened at $134.06 on Friday. The firm has a 50-day moving average of $139.59 and a 200-day moving average of $132.87. The company has a market cap of $166.40 billion, a P/E ratio of 19.80, a P/E/G ratio of 1.80 and a beta of 0.31. The company has a debt-to-equity ratio of 0.98, a current ratio of 1.55 and a quick ratio of 1.40. Gilead Sciences, Inc. has a one year low of $95.29 and a one year high of $157.29.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Thursday, May 7th. The biopharmaceutical company reported $2.03 EPS for the quarter, beating the consensus estimate of $1.91 by $0.12. The company had revenue of $6.96 billion during the quarter, compared to the consensus estimate of $6.91 billion. Gilead Sciences had a net margin of 28.90% and a return on equity of 49.46%. The firm’s revenue for the quarter was up 4.4% on a year-over-year basis. During the same quarter in the prior year, the company posted $1.81 earnings per share. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. Equities research analysts forecast that Gilead Sciences, Inc. will post 8.62 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, June 29th. Stockholders of record on Monday, June 15th will be issued a $0.82 dividend. The ex-dividend date is Monday, June 15th. This represents a $3.28 annualized dividend and a dividend yield of 2.4%. Gilead Sciences’s dividend payout ratio is currently 48.45%.

Analysts Set New Price Targets

GILD has been the topic of several research reports. Weiss Ratings restated a “buy (b)” rating on shares of Gilead Sciences in a report on Thursday, January 22nd. Deutsche Bank Aktiengesellschaft upped their price objective on shares of Gilead Sciences from $135.00 to $155.00 and gave the stock a “buy” rating in a report on Wednesday, February 11th. Rothschild & Co Redburn upped their price objective on shares of Gilead Sciences from $159.00 to $170.00 and gave the stock a “buy” rating in a report on Tuesday, February 17th. Leerink Partners upped their price objective on shares of Gilead Sciences from $146.00 to $148.00 and gave the stock an “outperform” rating in a report on Wednesday, February 11th. Finally, Daiwa Securities Group upped their price objective on shares of Gilead Sciences from $129.00 to $161.00 and gave the stock an “outperform” rating in a report on Wednesday, February 25th. Twenty-four research analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $157.35.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.